Sean Shelby began his career in cancer research in 1997 at the University of Colorado, Boulder. He worked with Dr. Tad Koch and his research team focusing on the design, synthesis and evaluation of drugs targeting breast, prostate, lung, liver and pancreatic cancer especially metastic resistant cancer. Shelby has years of experience in the Department of Chemistry and Biochemistry lab especially on the discovery of the natural product, anthracycline, anti-tumor drug, doxorubicin (Adriamycin), and its reaction with formaldehyde at the amino group to form a Doxazolidine.
Mr. Shelby founded Teleost Biopharmaceutical, Inc. in 2014 with the goal of developing products to help defend against skin maladies, detecting maladies and eventually researching products to treat those maladies. Dr. Victor Hruby is co-inventor with Sean on their first patented peptide product.
Dr. Victor J. Hruby, Ph.D
Dr. Victor J. Hruby serves as the Professor Emeritus of Chemistry at University of Arizona. Dr. Hruby’s research has been primarily in the chemistry, conformation-biological activity relationships, and molecular mechanisms of information transduction and of molecular diseases associated with peptide hormones and neurotransmitters and their receptors that modulate health, disease, and human behavior. Dr. Hruby serves as a Member of Scientific Advisory Board at Aileron Therapeutics Inc. Dr. Hruby serves as Member of the Scientific Advisory Board of New England Peptide LLC. He serves as Member of Scientific Advisory Board of CMD Bioscience LLC. He has published over 1000 articles, reviews, chapters, commentaries and editorials and has over 25 patents and patent filings. He has received numerous awards and honors, including the Alan E. Pierce Award (now the Merrifield Award) (1993). He received his B.S. and M.S. at the University of North Dakota. He then went to Cornell University where he received his Ph.D. with A. T. Bloomquist, and then was an Instructor at Cornell University Medical College with Vincent DuVigneaud, Nobel Laureate.
Dr. Minying Cai
Dr. Minying Cai is currently a research professor in the Department of Chemistry and Biochemistry at the University of Arizona. She has been working with Prof. Hruby for 13 years in the area of novel drug discovery for obesity, diabetes, cancer and pain. She is working on projects at the interface of chemical biology, molecular pharmacology and molecular biology within the areas of 1. Structure based drug design and synthesis of GPCR ligands, including developing selective human melanocortin receptors (hMCRs) ligands; 2. Developing novel biophysics tools for molecular imaging; novel molecular biomarker; high-throughput screening system, etc. 3. Exploiting novel scaffold via computational chemistry for small molecule therapeutics for energy balance and cancer study; 4. Exploring the novel physiological functions of melanocortin system involved. In collaboration with other investigators worldwide, we aim to identify and develop molecule modulators of GPCRs for the therapeutic treatment of metabolic and CNS disorders
Quan Nguyen concentrates his practice in paten procurement, opinion work (patentability/validity/freedom to operate analysis), intellectual property management, as well as general counseling with particular expertise in biotechnology, chemistry and medical devices. Prior to forming Nguyen & Tarbet, Quan was a Partner at Chandler & Udall in Tucson and a Partner at Cozen OConnor, a national law firm based in Philadelphia. Quan also has in house experience at Isis Pharmaceuticals, where he was Assistant Director of Patents.
Lawrence M. Hecker
Lawrence M. Hecker is a principal in the firm of Hecker & Muehlebach, PLLC. His practice focuses primarily in the areas of corporate law, business start up, capital formation transactions, and corporate finance. Mr. Hecker is a frequent panelist and speaker on securities regulations and corporate law and capital formation education seminars.
Mr. Hecker received both his Bachelor of Arts degree and his Juris Doctorate from the University of Arizona. He was Chief of Staff to Governor Bruce Babbitt from 1983 through 1984. He has served as Chairman of the Securities Regulations Section of the State Bar of Arizona. Mr. Hecker is listed in the 1993-2010 editions of Best Lawyers in America in the area of Corporate Law and was selected as Best Lawyer – Corporate Law for Tucson in 2010.
Conrad A. Plimpton
Conrad A. Plimpton is the Founder of Plimpton & Company and has been its Managing Director since 1979. Mr. Plimpton is a founder of Frontenac Company. Mr. Plimpton serves as the Chairman of the Inolex Chemical Company. Mr. Plimpton is a Partner of Corporate Development International (CDI Global) in pharma biotech; the founding Chairman of Comartis USA; founding shareholder and director of Troy Chemical; founded NeuroHealth Foundation in ZUG to sponsor MS Research at the University of Zurick; the Chairman of Cibola Technologies, Tucson Arizona. He served as the founding Chairman of the Board and Chief Executive Officer of Exide Electronics Group Inc. since 1982 (now Powerware Corporation) and served as its Secretary from 1982 to 1991. He served as an Investment Banker of Kuhn Loeb & Co. He served as Consultant of McKinsey & Company and its Director since 1980. He serves as the Chairman of the Board of Inolex Chemical Company and as a Director of Troy Corporation. He has been Director of MSDx, LLC since 2010. Mr. Plimpton holds M.B.A. from University of Chicago, a Master of Science in Astrophysics from University of Chicago, and a B.A. from Harvard University.
Robert L. Davis
Robert L. Davis is an alumnus of the University of Arizona, native Tucsonan, and a commercial real estate professional since 1985. He brokered many transactions involving the University of Arizona including the acquisition of the: UA Science & Technology Park, UA Mars Phoenix Mission Headquarters, UA Biosphere2, UA Phoenix Biomedical Plaza, and UA Bio5 Oro Valley. Davis was involved with IBMs sale to UA creating the Tech Park & did leases with IBM, Raytheon, & Microsoft in initial lease up of park, and represented the first bio-tech, materials tech, software tech, and internet tenants to locate there. He represented Target.com for their 975,000 SF Rita Ranch fulfillment center. His community activities include: UA Foundation Trustee, UA College Science Board, UA Bio5 Board, C-PATh Board, UA Alumni Association Board, UA Steele Childrens Research Center Board, Arizona Sonora Desert Museum Trustee, Tucson Conquistadores, Desert Angels, Carondelet Neurological Institute Advisory Board, DM 50, and many other boards, committees, and initiatives. Davis is deeply involved in Tucsons Start Up ecosystem including mentoring, advising, connecting, investing, and partnering with many entrepreneurs and enterprises. He was UA College of Science Alumnus of the year in 2004; and inducted in the UA McGuire Entrepreneurship Center and Pima County Sports Halls of Fame in 2010. He worked at the UA from 1973-1985 where he coached the first UA All-Americans in swimming and was Associate Athletic Director.
Grant D. Senner, MD
Grant D. Senner is a tested physician executive and entrepreneur with more than thirteen years of progressive healthcare leadership experience and brings proven success in achieving strategic, operational and financial objectives. His diverse background includes broad expertise in biomedical technology and commercialization, health finance, clinical program development, medical reimbursement and population health management. Upon completion of his Doctorate, Dr. Senner served as Fellow and Consultant for the state of Arizonas Medicaid agency where he focused on Centers for Medicare and Medicaid Services (CMS) reimbursement models and coordination of care for individuals with complex needs in a patient centered model. His career in healthcare spans the commercial, private, public and academic sectors. In 2012, he joined University of Arizona Health Sciences as Director of Special Projects and Strategic Initiatives and was responsible for analysis of market opportunities and support of grant and contract development in the areas of health policy, community health, evaluation research, comparative effectiveness research, and population health analytics. Dr. Senner continues to serve as a member of Faculty within the University of Arizona College Of Medicine, Tucson and is now part of the senior leadership team at Amnio Technology, LLC based in Phoenix, Arizona. As Principal and Founder of Sentinel Consulting Group, he assists life science companies with the rigors of strategic focus for commercialization and provides clinicians and facilities with solutions for complex challenges in practice management and healthcare delivery. An Honors graduate of The University of Arizona with a Bachelor of Science in Molecular and Cellular Biology, Dr. Senner attended The University of Arizona College of Medicine, Tucson and graduated with his Doctorate of Medicine in 2004. In 2014, his family established the Senner Endowment for Precision Health within University of Arizona Health Sciences, dedicated to support the use of genetic profiles to guide the diagnosis, prediction, treatment and prevention of disease. Dr. Senner joined the Board of Raising Special Kids in 2016 and has served on the Alumni Board of the University of Arizona College of Medicine, Tucson since 2010.
Hans Carstensen is an independent consultant affiliated with Next Level Building Enterprise Value, a consulting firm based in Seattle, Washington, providing Executive and Board Services to entrepreneurs and companies of all sizes across an array of industries. He serves as an independent advisor to non-profit organizations, start-up enterprises, established small businesses and aspiring entrepreneurs. Appointed President/CEO and member of the board of directors for Shenandoah Life Insurance Company in Roanoke, Virginia, Mr. Carstensen was appointed to lead the Company out of four years in bankruptcy, Mr. Carstensen has been President/CEO and a member of the board of directors for Aviva Life Insurance Company based in Boston, Massachusetts. Aviva Life and its associated subsidiaries comprised the U.S. operations of Aviva plc, which was headquartered in London and at that time the fifth largest insurance conglomerate in the world. Mr. Carstensen currently serves on several non-profit boards. He received his MBA in finance and his BA in Political Science from Stanford University.
Dr. Karl Lintner
Dr. Karl Lintner obtained a Degree in Chemical Engineering from Vienna University (Austria) and a PhD in Biochemistry from the same University. After 10 years of Research on Biological Peptides at the Nuclear Research Centre in Saclay, France (>30 papers in biochemistry and biophysics published), he became Laboratory Manager, then Marketing Manager (product development and worldwide technical support) with the HENKEL Company, Düsseldorf, Germany.
He joined SEDERMA, the world-leading Active Ingredient supplier, in 1990 as Technical Director and later headed the company for ten years as Managing Director/CEO.
Presently, Karl Lintner is an Independent Consultant to the Cosmetic Industry (President of KAL’IDEES S.A.S.).
He also teaches classes on cosmetic chemistry and skin biology at the ISIPCA school of Perfumery, Cosmetics and Aroma in Versailles and serves as Editor-in-Chief of the Int. Journal of Cosmetic Science. He has filed several dozens of patents, published numerous articles and book chapters on cosmetic ingredients, and is an active member of SCC (chaired COSA in 2011) and SFC (France) He was awarded the prestigious “Maison de Navarre” Medal of the SCC in 2012 and won the In-Cosmetics Lifetime Achievement Award in 2013.
George Baxter has been a pharmacist for over 30 years. Baxter has worked with independent pharmacies, long term care, chain pharmacies, and hospital pharmacies. Additionally, Baxter was part of a compounding business which made products for dermatologists and plastic surgeons. During this time Baxter produced a hand cream for an area dermatologist that he sold to his customers. As founder of Paramount Pharmacy, Baxter was on the board for the Boulder County Immunization Committee. As a part of the committee, Baxter worked all over Boulder County with doctors and nurses educating the community about the importance of immunizations for children.
David Rosenberger worked for The Dow Chemical Company from 1976 to 2005 with roles in sales, marketing, business management, and business development mostly in Dow’s Specialty and Basic Polymer businesses. Experiences included sales, sales management, strategy, new product development, marketing and marketing management. While at Dow, David also had roles in Dow’s Venture group, was Business Development Manager for Dow Environmental business, and was Business Development Director for New Polymers and Central Research Coating and Energy Labs.
He worked for Materia Inc 2005-2008, a start-up catalyst technology company based on Nobel Prize winning technology from Caltech, as VP Business Development.
In 2008 David joined The Hallstar Co., a specialty chemical manufacturer of modifiers for the Plastics Industry and specialty natural and chemical ingredients for the Beauty Personal Care Industry as Business Development Director responsible for Business Development, Corporate Strategy, and M&A. In 2012 he became VP of Personal Care and International Operations (Asia, Europe and South America) and in 2014 became Sr VP Global Commercial Operations for Hallstar. David retired from Hallstar in 2017.